ERBB2 and breast cancer: Human epidermal growth factor receptor 2 positive (HER2+) breast cancer cells are recognized by trastuzumab and undergo opsonization, which results in cell death by antibody-dependent cellular cytotoxicity (ADCC) in the presence of peripheral blood mononuclear cells (PBMCs).